Observations on [35S] sulphated insulins

Concentrated insulins: the new basal insulins

INTRODUCTION Insulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also needed. AREAS COVERED This ...

The preparation of [35S]homocysteine thiolactone free of [35S]methionine.

The unambiguous study of homocysteine metabolism requires a source of [355]homocysteine completely free from contaminating [35S]methionine. Until now, such a reagent has not been readily available. Homocysteine is an important metabolite involved in methionine, cysteine and methylation metabolism. Homocysteine can be methylated to form methionine with either 5-methyltetrahydrofolate [1] or beta...

Animal Insulins - Current Status

There is no significant difference in the metabolic control with animal or human insulin. At present there is no clinical data comparing the diabetes related mortality and complications, with animal or human insulin. The earlier animal insulins were more immunogenic as compared to human insulin, but the present day highly purified monocomponent insulins are less antigenic and the difference in ...

Expression of ricin under control of three different promoters, Cauliflower mosaic virus 35S promoter (35S), dual enhanced Cauliflower mosaic virus 35S promoter (35S)

Biosimilar insulins: a European perspective

Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes th...